A SEC Filings

Agilent Technologies, Inc. has filed an 8-K report on August 26, 2026, to announce its financial results for the third fiscal quarter ended July 31, 2026. The filing primarily consists of a press release (Exhibit 99.1) detailing these results. Investors should note that Agilent provides both GAAP and non-GAAP financial information, emphasizing that the non-GAAP measures are intended to offer supplemental insights into operational performance and are used by management for internal comparisons and decision-making. These non-GAAP figures exclude items like restructuring and amortization, which can materially impact GAAP earnings, and are presented to give investors a view of the company's performance "through the eyes of management." While the specific financial figures are detailed in the attached press release, the core of this 8-K is the disclosure of the company's quarterly performance. Investors are encouraged to review Exhibit 99.1 for the detailed financial metrics, segment performance, and specific non-GAAP reconciliations, as this information is crucial for understanding the company's current operational health and future prospects. The company stresses that its non-GAAP information may differ from that of other companies and is not a substitute for GAAP reporting.

Agilent Technologies, Inc. announced on June 25, 2026, the successful closing of a $600 million offering of 4.900% Senior Notes due 2032. These notes were sold in a private placement to qualified institutional buyers and offshore investors. The offering was conducted under Rule 144A and Regulation S, with Citigroup Global Markets Inc., Mizuho Securities USA LLC, and SG Americas Securities, LLC acting as the initial purchasers. The issuance of these notes, governed by an indenture originally dated March 12, 2021, and supplemented by a Fourth Supplemental Indenture dated June 25, 2026, represents a significant debt financing for the company. The notes bear a fixed annual interest rate of 4.900%, payable semi-annually, and mature on January 15, 2032. While these notes are senior unsecured obligations, they are not guaranteed by any subsidiaries. The company has also entered into a registration rights agreement to facilitate an exchange offer for these notes, with provisions for additional interest if certain registration deadlines are not met.

Agilent Technologies, Inc. reported robust financial results for the period ended April 30, 2026. Total net revenue increased by 10% year-over-year for the quarter and 8% for the six-month period, driven by broad-based growth across all segments and geographic regions. Net income saw a significant increase, reaching $339 million in the quarter and $644 million year-to-date, up from $215 million and $533 million in the prior year, respectively. The company continues to execute on its strategic priorities, including investing in research and development and expanding its product and service portfolio. A notable event was the definitive agreement to acquire BC Midco I, Inc. for approximately $950 million, which is expected to close by the end of fiscal year 2026 and will be integrated into the Life Sciences and Diagnostics Markets segment. Agilent also announced its board declared a quarterly dividend of $0.255 per share. Despite global economic uncertainties, the company has effectively mitigated impacts from geopolitical tensions and tariffs through strategic initiatives.

Agilent Technologies, Inc. (A) filed an 8-K on May 27, 2026, primarily to disclose financial results for its second fiscal quarter ended April 30, 2026. The filing includes a press release (Exhibit 99.1) detailing these results, alongside an explanation of the company's use of non-GAAP financial measures. Investors should note that the company emphasizes providing these non-GAAP figures to offer a clearer view of operational performance and future prospects, supplementing its GAAP reporting. These non-GAAP measures exclude items such as restructuring and amortization, which management monitors but does not use for ongoing operating performance evaluation. Additionally, the 8-K announces a key leadership change within the finance department. Tim Downs has been appointed as the new Vice President, Chief Accounting Officer, and principal accounting officer, effective after the filing of the Q2 10-Q. This appointment follows the previously announced retirement of Rodney Gonsalves, who will remain with the company in a transitional role until January 2027. Mr. Downs brings extensive experience from Baker Hughes and prior roles at General Electric and Deloitte. His compensation package includes a base salary, bonus eligibility, a sign-on cash bonus, and a significant restricted stock unit grant.

Agilent Technologies, Inc. filed an 8-K report on May 4, 2026, primarily to disclose a significant executive appointment. The company announced the appointment of Michael Buckner as its new Chief Legal Officer (CLO). This appointment marks a key change in the company's senior leadership, filling a critical legal and compliance role. Investors should note that this information is being furnished under Regulation FD and is not considered "filed" for purposes of the Securities Exchange Act of 1934, meaning it does not carry the same legal liabilities as a formally filed document but still provides important operational updates.

Agilent Technologies, Inc. filed an 8-K on April 6, 2026, primarily to disclose a Transition and General Release Agreement with Bret DiMarco, dated March 31, 2026. While this filing doesn't contain typical financial results or operational updates, the agreement's existence suggests a departure or separation involving Mr. DiMarco, who may be a significant executive or board member. Investors should note that details of this agreement, such as severance packages or ongoing obligations, are not provided in this exhibit list. The filing also includes the standard Cover Page Interactive Data File.

Agilent Technologies, Inc. (A) filed an 8-K on April 3, 2026, primarily to disclose a Transition and General Release Agreement with Bret DiMarco, dated March 31, 2026. While the filing does not contain significant financial updates or operational changes, the agreement with Mr. DiMarco, a former executive, is a key event. The details of this agreement, likely outlining separation terms, compensation, and release of claims, are crucial for understanding potential future financial impacts or legal resolutions related to his departure. Investors should review the full agreement for specifics on severance, equity awards, and any non-compete or non-disparagement clauses that could affect the company.

Agilent Technologies, Inc. has filed an 8-K report detailing the outcomes of its Annual Meeting of Stockholders held on March 18, 2026. The most significant development for investors is the approval of amendments to the Company's Certificate of Incorporation and Bylaws, which will implement a phased declassification of the Board of Directors over a three-year period. This change, effective upon the filing of the Certificate of Incorporation with the Delaware Secretary of State on March 19, 2026, moves away from a classified board structure towards annual election of all directors. In addition to the governance changes, the meeting saw the election of four directors to three-year terms, with strong affirmative votes. Stockholders also overwhelmingly approved the company's executive compensation on a non-binding advisory basis and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year 2026. The high turnout and overwhelming approval of these proposals indicate broad shareholder support for the company's direction and governance.

Agilent Technologies, Inc. filed an 8-K on March 6, 2026, primarily to disclose its exhibits. The core of this filing is the inclusion of the Cover Page Interactive Data File, which is embedded within the Inline XBRL document. This exhibit format is standard for SEC filings and provides structured data for financial reporting and analysis tools. Investors should note that this particular 8-K does not contain any new material financial results, business updates, or material agreements, but rather focuses on the technical presentation of the company's reporting data. While this filing is routine in nature, it signifies Agilent's commitment to transparent and accessible financial disclosure through modern reporting standards. Investors can leverage the interactive data file to more easily extract and analyze the company's financial information. For deeper insights into Agilent's financial performance and strategic direction, investors should refer to other filings that contain more substantive business and financial disclosures, such as quarterly earnings reports (10-Q) or annual reports (10-K).

Agilent Technologies, Inc. reported total net revenue of $1,798 million for the three months ended January 31, 2026, a 7% increase year-over-year, with favorable foreign currency movements contributing 3 percentage points to this growth. Net income for the quarter was $305 million, a slight decrease from $318 million in the prior year period. While overall revenue grew, driven by increases across all segments and geographic regions, the company faced increased costs impacting gross and operating margins. Notably, higher tariffs, unfavorable business mix including the specialty CDMO business, wage increases, and restructuring costs contributed to a decrease in gross margin. Selling, general, and administrative expenses also saw a significant increase, partly due to transformation initiatives and restructuring costs. Despite these pressures, the company continues to invest in R&D and capacity expansion, particularly for nucleic acid-based therapeutics.

Agilent Technologies, Inc. (A) filed an 8-K on February 25, 2026, to announce its financial results for the first fiscal quarter ended January 31, 2026. The report primarily consists of a press release (Exhibit 99.1) detailing these results. Investors should note that the company is providing non-GAAP financial information alongside GAAP results to offer a clearer view of its ongoing operational performance and future prospects, as assessed by management. The company emphasizes that its non-GAAP measures are intended to supplement, not replace, GAAP reporting, offering insights into core financial performance and facilitating comparisons with historical data and competitors. These non-GAAP figures exclude certain items like restructuring and amortization expenses, which, while monitored by management, are not used to evaluate the company's core operating performance. Investors are encouraged to review the full press release for detailed financial figures and a comprehensive explanation of the non-GAAP metrics used.

Agilent Technologies, Inc. reported a 7% increase in net revenue to $6,948 million for the fiscal year ended October 31, 2025, compared to the previous year. This growth was driven by strong performance across all segments and geographic regions, with the Life Sciences and Diagnostics Markets segment showing particular strength with an 11% increase, partly due to the acquisition of BIOVECTRA. The company's net income remained stable at $1,303 million, favorably impacted by tax benefits. Agilent continued its focus on operational efficiency, including a restructuring initiative aimed at optimizing management structure and achieving cost savings. The company also actively managed its capital through share repurchases and dividend payments, demonstrating a commitment to shareholder returns. Despite the overall positive revenue trend, the company faced headwinds such as increased tariffs and shipping costs, which impacted gross margins. Agilent is actively implementing mitigation strategies to address these pressures. The company also highlighted its ongoing investment in research and development to maintain its competitive edge and expand its product and solution portfolios. Looking forward, Agilent remains optimistic about the long-term health of its key end markets, despite some customer funding uncertainties, and anticipates continued growth through strategic investments and market expansion.

Agilent Technologies, Inc. has filed an 8-K to report its financial results for the fourth fiscal quarter ended October 31, 2025. The filing primarily consists of a press release (Exhibit 99.1) detailing these results and provides significant emphasis on the company's use of non-GAAP financial measures. Agilent believes these non-GAAP metrics offer a more meaningful view of operational performance and allow investors to understand results from management's perspective, facilitating comparisons with historical data and competitors. This approach aims to provide greater transparency into the financial and operational decision-making processes of the company.

Agilent Technologies, Inc. (A) announced a significant leadership change with the appointment of Adam S. Elinoff as its new Senior Vice President and Chief Financial Officer (CFO), effective November 17, 2025. Mr. Elinoff brings extensive financial experience from his tenure at Amgen Inc., where he held various senior finance, strategy, and investor relations roles. This appointment marks the transition from Rodney Gonsalves, who has been serving as Interim CFO. The company has also outlined a comprehensive compensation package for Mr. Elinoff, including a base salary of $700,000, eligibility for an annual bonus, and substantial equity awards in the form of restricted stock units (RSUs) and performance-based RSUs. These awards are designed to incentivize long-term performance and retention, with vesting schedules and performance criteria tied to the company's financial success. The appointment and compensation details are intended to signal a strategic focus on financial leadership and stability.

Agilent Technologies, Inc. reported solid revenue growth for the third quarter and the first nine months of fiscal year 2025, with total net revenue increasing by 10% and 6% year-over-year, respectively. This growth was driven by strong performance across all segments, particularly Life Sciences and Diagnostics Markets, which saw a 14% increase in Q3 revenue, aided by the BIOVECTRA acquisition. Despite revenue growth, net income for the nine-month period decreased compared to the prior year, largely due to higher costs, including increased tariffs and shipping expenses, and unfavorable product mix. The company is actively managing these cost pressures through supply chain optimization and targeted pricing actions, aiming to mitigate impacts by fiscal year 2026. Agilent also demonstrated a continued commitment to returning capital to shareholders, with ongoing dividend payments and a substantial share repurchase program. While facing macroeconomic headwinds and increased operating expenses, the company maintains a positive outlook, focusing on innovation and customer experience to drive long-term growth in its key end markets. Liquidity remains strong, supported by robust operating cash flows and existing credit facilities.

Agilent Technologies, Inc. has filed an 8-K report on August 27, 2025, to announce its financial results for the third fiscal quarter ended July 31, 2025. The report primarily contains a press release detailing these results, which are presented on both a GAAP and non-GAAP basis. The company emphasizes the use of non-GAAP measures to provide investors with a clearer view of operational performance and future prospects, excluding items such as restructuring and amortization that management does not consider reflective of ongoing operational performance. Investors should note that the provided non-GAAP figures are supplementary and may differ from those presented by other companies. The press release, attached as Exhibit 99.1, offers a more detailed explanation of these non-GAAP adjustments and should be reviewed in conjunction with the company's official GAAP financial statements. The inclusion of this non-GAAP information is a consistent practice by Agilent to enhance transparency and comparability for its stakeholders.

Agilent Technologies, Inc. (A) filed an 8-K on August 8, 2025, primarily to announce changes to the compensation package for Mr. Gonsalves following his appointment as interim Chief Financial Officer and interim Principal Financial Officer. This change is effective July 31, 2025, and includes a bi-weekly salary stipend of $8,654 for the duration of his interim role. Additionally, Mr. Gonsalves will receive a grant of restricted stock units (RSUs) with a target value of $1,000,000, subject to the terms of Agilent's 2018 Stock Plan.

Agilent Technologies, Inc. (A) announced a significant leadership change in its finance department via an 8-K filing on July 15, 2025. Effective July 31, 2025, Robert W. McMahon will be stepping down as Senior Vice President and Chief Financial Officer (CFO). The company explicitly stated that Mr. McMahon's departure is amicable and not due to any disagreements concerning accounting practices, financial statements, internal controls, or operational matters, which should provide some reassurance to investors regarding financial integrity. In parallel, Agilent has appointed Rodney Gonsalves as the interim CFO and interim Principal Financial Officer, also effective July 31, 2025. Mr. Gonsalves is a known quantity within the company, currently serving as Vice President, Corporate Controller, and Principal Accounting Officer. This interim appointment aims to ensure a smooth transition and continuity in financial leadership. Investors will be monitoring the company's communication for further updates on a permanent CFO selection.

Agilent Technologies, Inc. reported net revenue of $1.67 billion for the third quarter of fiscal year 2025, representing a 6% increase year-over-year, with growth driven by its Life Sciences and Diagnostics Markets and Agilent CrossLab segments. For the first six months of fiscal year 2025, net revenue grew 4% to $3.35 billion. Net income for the quarter was $215 million, a decrease from $308 million in the prior year's quarter, impacted by increased restructuring expenses and other costs. The company is navigating a dynamic economic landscape, including inflationary pressures and tariff changes, and is implementing strategies to mitigate these impacts. Despite a decrease in net income for the quarter, driven largely by a significant restructuring charge of $56 million, the company maintained a healthy revenue growth trajectory. Agilent continues to invest in its core segments, particularly Life Sciences and Diagnostics Markets, supported by the BIOVECTRA acquisition. The company is also actively managing its capital structure through share repurchases and dividends, returning value to shareholders while strategically investing in manufacturing capacity expansion.

Agilent Technologies, Inc. has filed an 8-K report detailing its financial results for the second fiscal quarter ended April 30, 2025. The report primarily consists of a press release announcing these results, which is furnished as an exhibit. The company emphasizes its use of non-GAAP financial measures to provide investors with a clearer view of its operational performance and future prospects, supplementing its standard GAAP reporting. These non-GAAP measures are used internally by management to assess performance and make strategic decisions, offering insights into the company's core financial health by excluding items like restructuring and amortization that can impact GAAP earnings per share.

Agilent Technologies, Inc. announced significant governance changes on May 21, 2025, through an 8-K filing. The Board of Directors has been expanded from 10 to 12 members with the appointment of two new independent directors, Pascal Soriot and Judy Gawlik Brown. Mr. Soriot brings extensive leadership experience from the pharmaceutical industry, most notably as CEO of AstraZeneca, while Ms. Brown offers deep financial and operational expertise from roles at Amgen, Perrigo, and as founder of Downtown Advisory, along with her current independent director experience at Belden Inc. In addition to the board expansion, Agilent's bylaws were amended to lower the supermajority voting threshold for certain corporate actions from 80% to a simple majority. This change aims to streamline decision-making processes. Both new directors have been deemed independent and will receive standard non-employee director compensation. These moves suggest a strategic effort to enhance board oversight and potentially improve corporate agility.

Agilent Technologies, Inc. announced the resignation of Henrick Ancher-Jensen, Senior Vice President and President of Order Fulfillment and Supply Chain, effective June 1, 2025. Mr. Ancher-Jensen is departing to pursue another opportunity. This departure, while effective in early June, is being disclosed now to provide timely information to investors. The company has also filed its 8-K, which primarily serves to report this executive change and includes the standard Cover Page Interactive Data File as an exhibit. Investors should monitor any subsequent filings for information regarding the transition plan for Mr. Ancher-Jensen's responsibilities and the appointment of a successor, as this is a key role within the company's operational structure.

Agilent Technologies, Inc. (AGIL) has filed an 8-K report primarily disclosing the resignation of a key board member, Heidi Kunz, effective May 21, 2025. Ms. Kunz, who served on both the Compensation Committee and the Nominating/Corporate Governance Committee, is stepping down from her director role. Importantly, the filing explicitly states that her resignation is not a result of any disagreements related to the company's operations, policies, or practices. The company expressed gratitude for her contributions.

Agilent Technologies, Inc. filed an 8-K on March 17, 2025, detailing the outcomes of its Annual Meeting of Stockholders held on March 13, 2025. The meeting saw strong participation, with approximately 88.18% of outstanding shares represented. Key outcomes include the election of two new directors, Otis W. Brawley, M.D., and Mikael Dolsten, M.D., Ph.D., for three-year terms, with broad shareholder support. All other incumbent directors will continue in their roles. Furthermore, shareholders provided advisory approval for the compensation of named executive officers and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2025. The company also saw significant approval for amendments to its Certificate of Incorporation to remove supermajority voting requirements, indicating a move towards simpler governance. A shareholder proposal to elect directors annually also received substantial support, suggesting a preference for annual director elections.

Agilent Technologies, Inc. reported total net revenue of $1.681 billion for the third fiscal quarter ended January 31, 2025, a slight increase of 1% compared to the prior year period. This growth was driven by the Life Sciences and Diagnostics Markets segment, which saw a 4% increase, and the Agilent CrossLab segment, which grew by 1%. However, the Applied Markets segment experienced a 4% decline in revenue. Net income for the quarter was $318 million, down from $348 million in the same quarter last year, with diluted earnings per share of $1.11 compared to $1.18 in the prior year. Despite a slight revenue increase, the company saw a decrease in overall profitability and a decline in gross and operating margins. The company also repurchased $90 million of its common stock during the quarter and maintained its quarterly dividend, reflecting a continued commitment to returning capital to shareholders. Agilent's cash position remains strong, with cash and cash equivalents totaling $1.467 billion. The company has reorganized its reporting segments, and management anticipates a steady recovery in customer capital budgets while remaining optimistic about long-term market health.

Agilent Technologies, Inc. has announced a significant restructuring of its business segments, effective from November 2024, which is being formally disclosed in this 8-K filing. The company has reorganized into three new reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. This change is driven by a strategy to enhance market focus and customer centricity. Investors should note that this filing primarily serves to provide recast financial information for the company's Annual Report on Form 10-K for the year ended October 31, 2024, to reflect these new segment structures. It does not introduce new financial results or update the Management's Discussion and Analysis for events after the 10-K filing date. For the most current financial performance and forward-looking information, investors are directed to Agilent's subsequent Quarterly Report on Form 10-Q for the period ended January 31, 2025, and other SEC filings.

Agilent Technologies, Inc. has filed an 8-K report on February 26, 2025, to announce its financial results for the first fiscal quarter ended January 31, 2025. The report primarily consists of a press release (Exhibit 99.1) detailing these results. The company emphasizes its use of non-GAAP financial measures, stating they provide a more meaningful view of operational performance and are used by management for decision-making and comparisons. While the full financial details are within the attached press release, the key takeaway for investors is that Agilent is providing supplemental non-GAAP information to offer greater transparency into its core business performance. This approach excludes certain GAAP-recognized items like restructuring and amortization, which management monitors but does not consider indicative of ongoing operating performance. Investors should refer to Exhibit 99.1 for the specific figures and a detailed explanation of these non-GAAP metrics and their reconciliation to GAAP.

Agilent Technologies, Inc. reported a 5% decrease in net revenue for the fiscal year ended October 31, 2024, reaching $6.51 billion. This decline was primarily attributed to weakened customer capital expenditure spending, impacting both the Life Sciences and Applied Markets and Diagnostics and Genomics segments, particularly within the pharmaceutical sector. However, the Agilent CrossLab segment demonstrated resilience with a 5% revenue increase, driven by strong demand for repair and maintenance services across all end markets. The company maintained profitability with net income of $1.29 billion, slightly up from the previous year, supported by cost-saving initiatives and higher interest income. Agilent also completed a significant acquisition of BIOVECTRA for $915 million, expanding its contract development and manufacturing capabilities. The company continues to focus on enhancing customer experience and driving productivity, anticipating a gradual recovery in customer capital budgets while managing inflationary pressures through pricing strategies and cost-saving measures.

Agilent Technologies, Inc. has announced a significant reorganization of its operational structure, effective for financial reporting beginning with the quarter ending January 31, 2025. The company is shifting to a market-focused, customer-centric strategy, which will be reflected in three newly defined reportable business segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab. This change aims to better align the company's operations with its strategic goals and provide clearer insights into performance across these key areas. This 8-K filing provides investors with selected unaudited historical financial information recast under these new segments. While this information is being furnished and not formally filed for Section 18 liability, it offers a preview of how Agilent's past performance will be presented moving forward. Investors should note that prior periods will be restated accordingly, enabling a more consistent comparison once the new structure is fully implemented.

Agilent Technologies, Inc. has announced a significant reorganization of its operational structure, effective with its first quarter fiscal year 2025 results. The company will now report under three distinct business groups: Life Sciences and Diagnostics Markets Group, Applied Markets Group, and Agilent CrossLab Group. This strategic move aims to align the company's reporting structure with its operational focus, potentially leading to greater clarity for investors regarding segment performance and strategic initiatives within each area. This reorganization is a forward-looking development that investors should monitor closely. The new structure is expected to provide a more granular view of Agilent's performance across its key markets, enabling better assessment of growth drivers and strategic execution. While the filing does not provide financial details of the reorganization's impact, it signals a proactive approach by management to adapt its structure to evolving market dynamics and enhance operational efficiency and transparency.

Agilent Technologies, Inc. has filed an 8-K report on November 25, 2024, to announce its financial results for the fourth fiscal quarter ended October 31, 2024. The report primarily includes a press release (Exhibit 99.1) detailing these results. Investors should note that Agilent provides both GAAP and non-GAAP financial information, with the latter presented to offer a clearer view of operational performance and future prospects as seen by management. While the non-GAAP measures aim to enhance understanding of core financial performance by excluding items like restructuring and amortization, they are not a substitute for GAAP and may differ from non-GAAP presentations by other companies. The company emphasizes that these non-GAAP metrics are used internally for performance measurement and comparison. Investors are encouraged to review the full press release in Exhibit 99.1 for a comprehensive understanding of the financial outcomes and the detailed reconciliation between GAAP and non-GAAP figures.

Agilent Technologies, Inc. has successfully closed a public offering of $1.2 billion in aggregate principal amount of senior notes. This issuance comprises $600 million of 4.200% Senior Notes due 2027 and $600 million of 4.750% Senior Notes due 2034. The proceeds from this offering will be used to fund the company's operations and strategic initiatives. The new notes are unsecured and rank equally with Agilent's existing senior unsecured indebtedness. The terms include provisions for redemption by the company under specific conditions, including a 'Par Call Date' and a 'Change of Control Repurchase Event.' Notably, the 2027 Notes are subject to a special mandatory redemption at a higher principal amount (101%) if the 'BioVectra Acquisition' is not completed by a specified date or if Agilent decides not to proceed with it. This indicates the acquisition is a significant factor tied to the financing.

Agilent Technologies, Inc. has announced the issuance and sale of $1.2 billion in aggregate principal amount of senior notes through an underwritten public offering. The offering consists of $600 million of 4.200% Senior Notes due 2027 and $600 million of 4.750% Senior Notes due 2034. These notes are unsecured and will rank equally with other senior unsecured indebtedness of the company. The offering is expected to close on September 9, 2024, subject to customary closing conditions.

Agilent Technologies, Inc. filed a Current Report on Form 8-K to incorporate by reference information from its previous filings, specifically to reflect a change in its operating segment reporting structure. The company has recasted its historical financial segment information to align with a reorganization announced in the first quarter of fiscal year 2024. This reorganization moved the cell analysis business from the 'Life Sciences and Applied Markets' segment to the 'Diagnostics and Genomics' segment. This 8-K filing serves to update the presentation of segment data within previously filed documents, primarily the Annual Report on Form 10-K for the year ended October 31, 2023. Investors should note that this report does not contain new financial information or updates on subsequent events beyond the segment recasting. For the most current financial performance and events, investors should refer to Agilent's most recent Form 10-Q filing for the quarter ended July 31, 2024.

Agilent Technologies, Inc. reported a decrease in net revenue for the third quarter and the first nine months of fiscal year 2024 compared to the prior year periods, driven by decreased product sales in its Life Sciences and Applied Markets, and Diagnostics and Genomics segments. This decline was partially offset by revenue growth in the Agilent CrossLab segment. Despite lower revenues, the company saw a significant increase in net income for the quarter, primarily due to strong operational performance and a reduction in costs compared to the prior year, which was impacted by substantial asset impairment charges. Agilent also announced a significant acquisition of BIOVECTRA for $925 million, expected to close before calendar year 2025, signaling a strategic move to expand its capabilities. The company is actively managing its cost structure through restructuring initiatives, including headcount reductions, which contributed to improved operating margins year-over-year. Agilent continues to return capital to shareholders through dividends and a robust share repurchase program, with approximately $709 million remaining authorization under its 2023 repurchase program and a new $2.0 billion program set to begin in August 2024. Despite ongoing market challenges and customer capital expenditure pressures, particularly in China, Agilent remains optimistic about long-term growth prospects in its key end markets.

Agilent Technologies, Inc. has filed an 8-K report on August 21, 2024, to announce its financial results for the third fiscal quarter ended July 31, 2024. The report primarily consists of a press release (Exhibit 99.1) detailing these results. Agilent continues to emphasize its use of non-GAAP financial measures to provide a more insightful view of its operational performance and future prospects, explaining that these metrics are used internally by management and allow for better comparison to historical and competitor results, while also acknowledging that they exclude items like restructuring and amortization that impact GAAP figures.

Agilent Technologies, Inc. reported a decrease in net revenue for the third quarter and first six months of fiscal year 2024, down 8% and 7% respectively, compared to the prior year. This decline was primarily driven by the Life Sciences and Applied Markets segment and the Diagnostics and Genomics segment, impacted by customer capital expenditure pressures, particularly in the pharmaceutical market. The Agilent CrossLab segment showed resilience with revenue growth in both periods. Despite the revenue decline, net income remained stable, with $308 million reported for the third quarter and $656 million for the first six months, slightly up from the prior year. Operating cash flow significantly improved, reaching $818 million for the first six months of fiscal year 2024, up from $694 million in the comparable prior-year period. The company also announced a new restructuring plan (FY24 Plan) aimed at further cost reductions, involving approximately 500 employee reductions, with an estimated annual cost savings of $100 million. Additionally, a new $2.0 billion share repurchase program was approved, effective August 1, 2024.

Agilent Technologies, Inc. announced its financial results for the second fiscal quarter ended April 30, 2024, alongside a significant capital allocation update. The company is implementing a new stock repurchase program authorizing up to $2 billion of common stock, demonstrating confidence in its financial position and a commitment to returning value to shareholders. This program is set to begin on August 1, 2024, or upon the full utilization of the existing repurchase program, indicating a strategic approach to managing its capital. The company also reiterated its practice of providing non-GAAP financial measures, explaining their utility in offering a clearer view of operational performance by excluding items like restructuring and amortization. Investors are encouraged to review the accompanying press release (Exhibit 99.1) for a detailed breakdown of these results and a comprehensive understanding of the non-GAAP adjustments, which management uses for performance evaluation and strategic decision-making.

Agilent Technologies, Inc. (A) filed an 8-K on May 24, 2024, primarily detailing the compensation package for its newly appointed CEO, Mr. McDonnell. Effective June 1, 2024, Mr. McDonnell will receive an annual base salary of $1,075,000 and a target performance bonus of 125%. This compensation structure reflects the company's commitment to incentivizing its top executive. Further details include significant equity awards totaling $3,300,000, effective June 3, 2024, consisting of performance-based RSUs, time-based RSUs, and stock options. This award is part of Mr. McDonnell's total FY2024 equity award of $7,500,000, with a portion previously granted. Investors should note this filing focuses solely on executive compensation adjustments following the CEO transition and does not include operational or financial performance updates.

Agilent Technologies, Inc. (A) filed an 8-K on May 24, 2024, primarily announcing the departure of a board member, Hans E. Bishop. Mr. Bishop stepped down from the Board of Directors effective May 23, 2024, after serving since 2017. His departure is stated to be unrelated to any disagreements concerning the Company's operations, policies, or practices, which is a positive signal for investors regarding internal stability. This change resulted in a reduction of the Board size from eleven to ten directors. The company also issued a press release on May 23, 2024, to formally announce this board change. While this is a change in board composition, it does not appear to signal any immediate operational or strategic shifts for Agilent.

Agilent Technologies, Inc. (A) filed an 8-K on May 1, 2024, primarily to announce a significant leadership transition. Effective May 1, 2024, Michael McMullen retired as President and CEO and from the Board of Directors, concluding his tenure. Mr. McMullen will remain with the company in a senior advisor role until October 31, 2024, providing a transition period. In conjunction with Mr. McMullen's retirement, the Board of Directors has appointed Padraig McDonnell as the new President and CEO, effective May 1, 2024. Mr. McDonnell has also been appointed to the Board. Investors should note that the Board is scheduled to review and potentially adjust Mr. McDonnell's compensation package on May 21, 2024. A press release detailing Mr. McDonnell's appointment was issued on the same day.

Agilent Technologies, Inc. (A) filed an 8-K on March 15, 2024, detailing the results of its Annual Meeting of Stockholders held on March 14, 2024. The meeting saw strong participation, with approximately 91% of outstanding shares represented. All proposals presented to shareholders received overwhelming approval, indicating robust support for the company's current leadership and strategic direction. Key outcomes include the election of four directors to three-year terms, the approval of executive compensation through a non-binding advisory vote, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024. Additionally, a shareholder proposal regarding a simple majority vote was also approved. The overwhelming support across all proposals suggests shareholder confidence in Agilent's governance and financial oversight.

Agilent Technologies, Inc. reported net revenue of $1.658 billion for the third quarter of fiscal year 2024, a decrease of 6% compared to the prior year. This decline was primarily driven by a 9% decrease in product revenue, influenced by customer capital expenditure pressures, particularly in the pharmaceutical and chemical/advanced materials markets. Despite the revenue dip, the company maintained a strong operational performance with net income of $348 million, nearly flat year-over-year. Operating cash flow significantly improved, reaching $485 million compared to $296 million in the prior year. Agilent also continued its commitment to shareholders through dividends and has a substantial remaining authorization for share repurchases. The company is navigating a challenging macroeconomic environment, especially in China, and expects ongoing customer capital expenditure pressures. However, Agilent remains optimistic about its long-term growth prospects across its key end markets, driven by its differentiated product solutions and focus on customer experience and productivity.

Agilent Technologies, Inc. filed an 8-K on February 27, 2024, to announce its financial results for the first fiscal quarter ended January 31, 2024. The report primarily consists of a press release (Exhibit 99.1) detailing these results. The company emphasizes its use of non-GAAP financial measures to offer investors a clearer view of operational performance and future prospects, as seen through management's eyes, alongside the standard GAAP reporting. This disclosure serves to provide investors with supplemental information that management uses internally for performance evaluation and comparisons. While these non-GAAP measures exclude items like restructuring and amortization that impact GAAP earnings, they are presented to enhance transparency and allow for a better understanding of the company's core ongoing financial performance. Investors should note that the specific non-GAAP metrics used by Agilent may differ from those reported by other companies.

Agilent Technologies, Inc. (A) announced on February 21, 2024, that its President and CEO, Michael McMullen, will retire from his roles on May 1, 2024. Mr. McMullen will transition to a senior advisor role until October 31, 2024. This leadership change marks the end of a significant tenure for Mr. McMullen. Concurrently, the Board has appointed Padraig McDonnell, currently a Senior Vice President, as Chief Operating Officer (COO) and CEO-elect. Mr. McDonnell is slated to assume the CEO position upon Mr. McMullen's retirement and will be nominated to the Board. His appointment is accompanied by a revised compensation package, including a base salary increase, enhanced performance-based compensation targets, and significant equity awards comprising stock options, RSUs, and performance-based RSUs, reflecting his new responsibilities and long-term commitment to Agilent.

Agilent Technologies, Inc. (A) has filed an 8-K report on January 5, 2024, to disclose a change in its business segment reporting structure. Effective for the quarter ending January 31, 2024, the company is moving its Cell Analysis Division from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG). This strategic reorganization aims to enhance growth opportunities within both affected divisions. This change will result in a restatement of prior period financial information to align with the new segment structure. Investors should note that the report includes selected segment information for historical periods (fiscal quarters and years from 2021 to 2023) reflecting this updated organization, which will be incorporated into future financial statements. The information provided is furnished and not deemed filed under Section 18 of the Securities Exchange Act.

Agilent Technologies, Inc. reported net revenue of $6.833 billion for the fiscal year ended October 31, 2023, a slight decrease compared to the prior year, primarily due to weaker demand in China and pressures on customer capital expenditures impacting the Life Sciences and Applied Markets segment. However, the Diagnostics and Genomics segment saw a slight increase, and the Agilent CrossLab services business demonstrated robust growth of 8%. The company incurred significant asset impairment charges of $270 million related to the exit of its Resolution Bioscience business, which impacted net income, though overall net income remained stable year-over-year at $1.240 billion. Agilent continued its focus on capital allocation, repurchasing $476 million of its stock under its 2023 repurchase program and paying $265 million in dividends. The company also announced a new restructuring plan in fiscal year 2023, involving a workforce reduction and facility consolidation, expected to yield $80 million in annual cost savings. Looking ahead, Agilent anticipates a challenging macroeconomic environment but remains optimistic about long-term growth opportunities across its key end markets.

Agilent Technologies, Inc. has announced a significant change in its reporting structure, moving its Cell Analysis Division into its Diagnostics and Genomics Group, effective with its first quarter fiscal 2024 results. This strategic realignment is intended to better align operations and potentially enhance reporting clarity for investors. The company plans to provide three years of historical financial data adjusted for this new structure in January 2024, facilitating a more accurate comparison of past and future performance across these segments.

Agilent Technologies, Inc. (A) filed an 8-K on November 20, 2023, to announce its financial results for the fourth fiscal quarter ended October 31, 2023. The report primarily consists of a press release (Exhibit 99.1) detailing these results. The company emphasizes its use of non-GAAP financial information to provide investors with a clearer view of its core operational performance and future prospects, as measured by management. This non-GAAP information supplements GAAP results by excluding certain items like restructuring and amortization, which are monitored but not used for ongoing performance assessment.

Agilent Technologies, Inc. has announced a significant leadership change with the resignation of Sam Raha, Senior Vice President and President of the Diagnostics and Genomics Group (DGG). Mr. Raha will be departing the company on December 8, 2023, to pursue another opportunity. This departure marks the end of his tenure leading a critical segment of Agilent's business. Investors should monitor the company's succession plan and the transition process within the DGG segment, as leadership stability is crucial for operational continuity and strategic execution.